Trillium Therapeutics Inc.(Toronto Stock Exchange : TRIL)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| TSRO | TESARO, Inc. | -1.07% | 73.69 | 14.4% | $580.10m | |
| AMGN | Amgen Inc. | -2.76% | 192.07 | 1.2% | $565.07m | |
| GILD | Gilead Sciences, Inc. | -2.64% | 65.57 | 0.9% | $530.36m | |
| CELG | Celgene Corporation | -2.21% | 68.20 | 1.2% | $520.26m | |
| BIIB | Biogen Inc. | -1.75% | 314.55 | 1.3% | $359.40m | |
| ILMN | Illumina, Inc. | -2.44% | 326.46 | 3.5% | $350.15m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.70% | 381.17 | 2.6% | $273.12m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -1.94% | 170.06 | 1.9% | $226.47m | |
| A | Agilent Technologies, Inc. | -2.49% | 69.37 | 1.5% | $225.54m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -2.67% | 109.43 | 2.0% | $146.61m | |
| INCY | Incyte Corporation | -1.55% | 66.25 | 2.5% | $97.76m | |
| EXAS | Exact Sciences Corporation | 0.68% | 68.31 | 25.3% | $93.39m | |
| SRPT | Sarepta Therapeutics, Inc. | -2.05% | 119.52 | 15.4% | $90.77m | |
| NKTR | Nektar Therapeutics | -3.92% | 36.51 | 5.5% | $84.08m | |
| SGEN | Seattle Genetics, Inc. | -0.85% | 60.48 | 6.6% | $81.91m |
Company Profile
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company, which engages in the development of innovative therapies for the treatment of cancer. Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The company was founded on March 31, 2004 and is headquartered in Toronto, Canada.